The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for DM Shackleford


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.EBI
University of Cape Town
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.EBI
Progen Pharmaceuticals
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.EBI
Glaxosmithkline
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.EBI
University of Washington
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).EBI
Cytopia Research
Development of [EBI
Monash University
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.EBI
Medicines For Malaria Venture
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.EBI
Medicines For Malaria Venture
Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.EBI
University of Melbourne
Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.EBI
University of Wollongong
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).EBI
University of Nebraska Medical Center
Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.EBI
University of Washington
Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents.EBI
Monash University (Parkville Campus)
Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.EBI
Epichem
Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.EBI
Epichem
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.EBI
University of Liverpool
Autotaxin inhibitorsBDB
Novartis